Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies

Urologia Internationalis

Volumn 94, Issue 3, 2015, Pages 319-325

  Kaufmann, Sascha ^a,b   Kruck, Stephan ^a   Kramer, Ulrich ^a   Gatidis, Sergios ^a   Stenzl, Arnulf ^a   Roethke, Matthias ^c   Scharpf, Marcus ^b   Schilling, David ^a  

^a Department of Radiology ^*  (China)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Diagnostic performance; MRI guided biopsy; Prostate cancer; Systematic transrectal ultrasound guided biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOPSY DEVICE; BIOPSY GUN; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY; BIOPSY; COMPARATIVE STUDY; ECHOGRAPHY; FACTUAL DATABASE; LABORATORY DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX;

AGED; BIOPSY; DATABASES, FACTUAL; FALSE NEGATIVE REACTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX;

EID: 84928414258     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000365397     Document Type: Article

References (23)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Kwiatkowski M, Lujan M, Auvinen A: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
2. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr: Prevalence of prostate cancer among men with a prostatespecific antigen level or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
3. Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Sacca A, Pellucchi F, Suardi N, Abdollah F, Montorsi F, Rigatti P, Scattoni V: Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int 2012; 89: 126-135.
4. Colleselli D, Schilling D, Lichy MP, Hennenlotter J, Vogel UH, Krueger SA, Kuehs U, Schlemmer HP: Topographical sensitivity and specificity of endorectal coil magnetic resonance imaging for prostate cancer detection. Urol Int 2010; 84: 388-394.
5. Anastasiadis AG, Lichy MP, Nagele U, Kuczyk MA, Merseburger AS, Hennenlotter J, Corvin S, Sievert KD, Claussen CD, Stenzl A, Schlemmer HP: MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006; 50: 738-748; discussion 748-749.
6. Beyersdorff D, Taymoorian K, Knosel T, Schnorr D, Felix R, Hamm B, Bruhn H: MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol 2005; 185: 1214-1220.
7. Engelhard K, Hollenbach HP, Kiefer B, Winkel A, Goeb K, Engehausen D: Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol 2006; 16: 1237-1243.
8. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, van Oort IM, Witjes JA, Futterer JJ, Barentsz JO: Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183: 520-527.
9. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombai B, Villers A, van der Meulen J, Emberton M: Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011; 59: 477-494.
10. Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M: MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology 2005; 234: 576-581.
11. Franiel T, Stephan C, Erbersdobler A, Dietz E, Maxeiner A, Hell N, Huppertz A, Miller K, Strecker R, Hamm B: Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding -multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259: 162-172.
12. Eggert T, Khaled W, Wenske S, Ermert H, Noldus J: Impact of elastography in clinical diagnosis of prostate cancer. A comparison of cancer detection between B-mode sonography and elastography-guided 10-core biopsies (in German). Urologe A 2008; 47: 1212-1217.
13. Brock M, von Bodman C, Palisaar RJ, Loppenberg B, Sommerer F, Deix T, Noldus J, Eggert T: The impact of real-time elastography guiding a systematic prostate biopsy to improve cancer detection rate: a prospective study of 353 patients. J Urol 2012; 187: 2039-2043.
14. Loch T: Prostate cancer diagnostics: innovative imaging in case of multiple negative biopsies. World J Urol 2011; 29: 607-614.
15. Taverna G, Morandi G, Seveso M, Giusti G, Benetti A, Colombo P, Minuti F, Grizzi F, Grazziotti P: Colour Doppler and microbubble contrast agent ultrasonography do not improve cancer detection rate in transrectal systematic prostate biopsy sampling. BJU Int 2011; 108: 1723-1727.
16. Loch T: Computerized transrectal ultrasound (C-TRUS) of the prostate: detection of cancer in patients with multiple negative systematic random biopsies. World J Urol 2007; 25: 375-380.
17. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F: Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52: 1309-1322.
18. Zaytoun OM, Stephenson AJ, Fareed K, El-Shafei A, Gao T, Levy D, Jones JS: When serial prostate biopsy is recommended: most cancers detected are clinically insignificant. BJU Int 2012; 110: 987-992.
19. Turkbey B, Shah VP, Pang Y, Bernado M, Xu S, Kruecker J, Locklin J, Baccala AA, Rastinehad AR, Merino MJ, Shih JH, Wood BJ, Pinto PA, Choyke PL: Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011; 258: 488-495.
20. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, Scheenen T, Futterer J, Bouwense S, van Oort I, Schroder F, Huisman H, Barentsz J: Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core ultrasound prostate biopsy cohort. Eur Urol 2012; 61: 177-184.
21. Bott SR, Young MP, Kellett MJ, Parkinson MC; Contributors to the UCL Hospitals' Trust Radical Prostatectomy Database: Anterior prostate cancer: is it more difficult to diagnose? BJU Int 2002; 89: 886-889.
22. Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A: MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2012; 30: 213-218.
23. Schimmoller L, Quentin M, Arsov C, Lanzman RS, Hiester A, Rabenalt R, Antoch G, Albers P, Blondin D: Inter-reader agreement of the ESUR score for prostate MRI using inbore MRI-guided biopsies as the reference standard. Eur Radiol 2013; 23: 3185-3190.